Chung, Lawrance K.
Pelargos, Panayiotis E.
Chan, Ann M.
Demos, Joanna V.
Lagman, Carlito
Sheppard, John P.
Nguyen, Thien
Chang, Yu-Ling
Hojat, Seyed A.
Prins, Robert M.
Liau, Linda M.
Nghiemphu, Leia
Lai, Albert
Cloughesy, Timothy F.
Yong, William H.
Gordon, Lynn K.
Wadehra, Madhuri
Yang, Isaac
Funding for this research was provided by:
National Cancer Institute (CA163971)
Article History
Received: 28 August 2017
Accepted: 28 August 2017
First Online: 8 September 2017
Compliance with ethical standards
:
: L.K.C. was partially supported by the AMA Foundation Seed Grant and the AΩA Carolyn L. Kuckein Student Research Fellowship. P.P. was partially supported by the ABTA Medical Student Summer Fellowship. C.L. was partially supported by the Gurtin Skull Base Research Fellowship. J.P.S. and T.N. were supported by the David Geffen Medical Scholarship. M.W. was partially supported by the NCI R01 Grant (CA163971). I.Y. was partially supported by the UCLA Visionary Ball Fund Grant, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research UCLA Scholars in Translational Medicine Program Award, the Jason Dessel Memorial Seed Grant, the UCLA Honberger Endowment Brain Tumor Research Seed Grant, and the Stop Cancer! Research Career Development Award.
: MW. and L.K.G. are inventors on the University of California patents related to EMP2 as a target for antibody therapy. They are also the founders of Paganini Biopharma. The remaining authors have no personal or institutional financial interest in drugs, materials, or devices described in this study.